Security key
74346N701
Propanc Biopharma, Inc. - Common Stock, par value $0.001 per share (PPCB)
CUSIP: 74346N701
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 112,107
- Total 13F value
- $190,731
- Share change
- +112,107
- SEC-reported price per share
- $1.70
- Number of holders
- 3
- Value change
- +$190,731
- Number of buys
- 3
- Shares outstanding
- 12,703,253
Holder snapshot
5 signals
Security identity
1 source field
Report period
Q3 2025
Institutions
3
Top holders
3
PPCB full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Propanc Biopharma, Inc. SEC filings
Propanc Biopharma, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 74346N701
Recent filing periods:
Ownership snapshot
Top reported holders of PPCB - Propanc Biopharma, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Josef Zelinger
Disclosed value leader
—
Comparable rows
0/3
Latest evidence
05 Jul 2023
3/4/5
Some rows are evidence-backed but not safely comparable across classes.
3 rows are not safely comparable across share classes.
Quick read
SEC ownership evidence is available, but the rows are not safely comparable across share classes.
0 of 3 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Detailed SEC evidence table Showing 1-3 of 3 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Josef Zelinger |
3/4/5
Director
|
—
mixed-class rows
|
—
15,002,805 shares
mixed-class rows
|
— | 05 Jul 2023 |
| James Andrew Nathanielsz |
3/4/5
CEO/CFO, Director
|
—
class O/S missing
|
—
8,728,004 shares
|
— | 17 Aug 2021 |
| Julian Norman Kenyon |
3/4/5
Chief Scientific Officer, Director
|
—
class O/S missing
|
—
3,420,005 shares
|
— | 17 Aug 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
3
Shares
112,107
Rows available
3
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q4 2025 Across Filers
Q4 2025 holders
4
Q3 2025 holders
3
Holder diff
-1
| Investor | Q4 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q4 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend